Crown Bioscience, Inc.

ST. LOUIS, Feb. 25, 2025 /PRNewswire/ -- Panome Bio, a leading discovery services company, announced the addition of accomplished biotechnology leader Jean-Pierre Wery to its Board of Directors. Dr. Wery, a seasoned executive with a proven track record in scaling life sciences service companies, brings invaluable expertise to Panome Bio as it rapidly expands its operations to meet increasing customer demand. Continue Reading Panome Bio leverages metabolomics, proteomics, and multi-omic integration workflows to help biopharma discover novel biology, unravel mechanistic insights, and optimize biological systems. The company has seen substantial growth since launch in 2022, including a financing partnership with Telegraph Hill Partners and a continued expansion of their service offerings, most recently having added a suite of metabolomic tools for interrogating microbiome function. Panome Bio announces the addition of biotechnology leader Jean-Pierre Wery to its Board of Directors. Post this "We are thrilled to welcome Dr. Wery to our Board of Directors," said Edward Weinstein, CEO and Co-founder of Panome Bio. "His deep industry knowledge and strategic vision will be instrumental in guiding Panome Bio's next phase of growth. With JP's expertise, we are confident in our ability to deliver groundbreaking solutions that will transform the future of discovery sciences." Dr. Wery has substantial experience scaling CROs including as CEO of Crown Bioscience where he grew the services company to over $100M in annual revenue. "Panome Bio is at the forefront of a new era in drug discovery and clinical development," said JP Wery. "I am excited to join the Board of Directors and contribute to the company's mission of accelerating the adoption and impact of multi-omic approaches to discovery research." "JP's appointment further strengthens Panome Bio's Board of Directors and positions the company for continued success. We are confident that his leadership will drive significant value for the broader scientific community" said Deval Lashkari, Senior Partner from Telegraph Hill Partners. Deval Lashkari and his partner at Telegraph Hill, Rob Capone, are also part of Panome Bio's Board of Directors along with Edward Weinstein, and David Smoller, serial entrepreneur and Panome Bio Co-founder. About Panome Bio: Panome Bio is a contract research organization performing metabolomics, proteomics, and integrated multi-omics data analysis to help clients further their research in disease and drug development. Panome Bio provides a comprehensive workflow including experimental design, sample preparation and analysis, and data processing. For more information, please visit , follow us on LinkedIn at , or email at [email protected]. About Telegraph Hill Partners: Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology, and healthcare companies. For more information, please see . Contact Information: Alexandra Harrison Director of Marketing, Panome Bio [email protected] ‪(314) 632-6588 SOURCE Panome Bio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN DIEGO--( BUSINESS WIRE )--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has been honored with the 2024 Fierce CRO Award for Excellence in Client Service and Partnership. This prestigious award recognizes Crown Bioscience's outstanding collaboration, communication, and commitment to delivering excellence for its life sciences clients. The Fierce CRO Awards, hosted annually by Fierce Biotech, celebrate the achievements of leading CROs that demonstrate innovation and leadership in accelerating drug development. Winners in this category are selected based on their commitment to building strong partnerships and providing an exceptional client experience. "Winning this award is a true testament to our team’s dedication to going above and beyond for our clients," said Dr. Jonny McMichael, Vice President of Client Experience and Enablement at Crown Bioscience. "We aim to accelerate the journey of new therapies by collaborating closely with our partners across the drug development continuum." Crown Bioscience stood out for its innovative preclinical research capabilities, transparent communication practices, and unwavering focus on delivering quality and value to clients. Specific achievements highlighted include the company's Customer Satisfaction Program , which generates unfiltered feedback scores to demonstrate its commitment to service and customer excellence. "This recognition motivates us to continue raising the bar for the CRO industry," Dr. McMichael added. "We are thankful to our entire team for making Crown Bioscience a trusted, client-focused partner in the mission to bring new treatments to patients faster and more efficiently." The full Fierce CRO Awards report profiling all winners is available here . Crown Bioscience's award-winning capabilities can be explored at www.crownbio.com . About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com

The combined expertise is expected to ensure a more effective path to clinic. Credit: Salov Evgeniy/Shutterstock. CTI Clinical Trial & Consulting Services (CTI) and Crown Bioscience have announced a strategic partnership aimed at bolstering consulting services for oncology drug development. The collaboration brings together CTI’s clinical and regulatory expertise with Crown Bioscience’s preclinical and translational models, aiming to streamline the transition of oncology compounds from discovery to early-phase global studies. It is set to benefit customers by providing expert guidance that enhances the efficiency of oncology drug development. CTI Global Laboratory Services business development vice-president Ryan Gifford stated: “Crown Bioscience’s leadership in early-phase oncology research and suite of preclinical services complement CTI’s broad spectrum of capabilities. “Together, we can offer enhanced support to our oncology clients and deepen our commitment to advancing cancer research.” See Also: FDA approves updated mRNA vaccines for Covid-19 Verve Therapeutics gets grant for gene editing compositions to lower ldl cholesterol levels The combined expertise is expected to ensure an effective path to clinic, support long-term success in drug development and accelerate the delivery of new oncology treatments to patients. Through the alliance, customers will have access to a range of consulting services designed to foster an integrated approach to drug development. These services include strategic preclinical development planning, study data analysis and interpretation, de novo assay development and regulatory guidance. Crown Bioscience commercial senior vice-president Alex Slater stated: “Crown Bioscience has an established reputation for exceeding the typical services offered by a regular CRO [contract research organisation]. “This initiative unites deep-seated expertise spanning all phases of drug development, marking a pivotal step towards delivering a true translational offer to our clients.” In November 2023, Crown Bioscience launched its service offering , OrganoidXplore to meet the demands of research initiatives by offering a diverse selection of models that cover a wide spectrum of genetic backgrounds and mutations.